Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies.
Eur J Intern Med
; 25(5): 482-4, 2014 Jun.
Article
em En
| MEDLINE
| ID: mdl-24495663
ABSTRACT
BACKGROUND:
Hepatitis B virus (HBV) reactivation in patients positive for antibody to HB core antigen (anti-HBc), negative for HB surface antigen (HBsAg) and HBV-DNA (potential occult HBV carriers), treated with anti-tumor necrosis factor (TNF)α, is a debated question. The aim of the study was to evaluate the safety of anti-TNFα therapy in anti-HBc positive/HBsAg negative subjects with rheumatoid arthritis (RA) and spondyloarthropathy (SpA).METHODS:
All consecutive HBsAg negative RA and SpA outpatients referring to the Immuno-Rheumatology Institute at the S. Andrea hospital, Sapienza, University of Rome who had to undergo anti-TNFα therapy.RESULTS:
Among the 169 enrolled subjects, 20 (12%) were potential occult HBV carriers (anti-HBc positive, HBsAg and HBV-DNA negative patients with or without anti-HBs). During the follow-up (mean ± SD 45 ± 22 months), aminotransferases and HBV-DNA, tested every two and six months respectively, did not change.CONCLUSION:
This study confirms the substantial safety of anti-TNFα therapy in potential occult HBV carriers RA and SpA patients.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Ativação Viral
/
Vírus da Hepatite B
/
Fator de Necrose Tumoral alfa
/
Antirreumáticos
/
Espondiloartropatias
/
Imunossupressores
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Eur J Intern Med
Assunto da revista:
MEDICINA INTERNA
Ano de publicação:
2014
Tipo de documento:
Article
País de afiliação:
Itália